Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Mereo BioPharma (MREO) over the last 4 years, with Q3 2025 value amounting to $4.8 million.

  • Mereo BioPharma's Non-cash Items fell 7973.02% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 7973.02%. This contributed to the annual value of $15.8 million for FY2024, which is 9401.63% up from last year.
  • Per Mereo BioPharma's latest filing, its Non-cash Items stood at $4.8 million for Q3 2025, which was down 7973.02% from $10.1 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma's Non-cash Items ranged from a high of $23.9 million in Q3 2024 and a low of $6000.0 during Q4 2022
  • Its 4-year average for Non-cash Items is $11.8 million, with a median of $10.1 million in 2025.
  • Per our database at Business Quant, Mereo BioPharma's Non-cash Items soared by 13526666.67% in 2023 and then tumbled by 7973.02% in 2025.
  • Mereo BioPharma's Non-cash Items (Quarter) stood at $6000.0 in 2022, then soared by 135266.67% to $8.1 million in 2023, then skyrocketed by 94.02% to $15.8 million in 2024, then crashed by 69.29% to $4.8 million in 2025.
  • Its Non-cash Items was $4.8 million in Q3 2025, compared to $10.1 million in Q2 2025 and $7.0 million in Q1 2025.